[go: up one dir, main page]

MA28687B1 - Composes organiques - Google Patents

Composes organiques

Info

Publication number
MA28687B1
MA28687B1 MA29571A MA29571A MA28687B1 MA 28687 B1 MA28687 B1 MA 28687B1 MA 29571 A MA29571 A MA 29571A MA 29571 A MA29571 A MA 29571A MA 28687 B1 MA28687 B1 MA 28687B1
Authority
MA
Morocco
Prior art keywords
quinolin
substituted oxy
organic compounds
halo
hydroxy
Prior art date
Application number
MA29571A
Other languages
English (en)
Inventor
Olivier Lohse
Caspar Vogel
Gerhard Penn
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32799952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28687(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA28687B1 publication Critical patent/MA28687B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/04—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D251/06—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un procédé permettant de préparer des oxy-5-((R)-2-halo-l-hydroxy-éthyl)-(lH)-quinolin-2-ones substitués à la position 8 ou des solvates acceptables de ceux-ci. Le procédé susmentionné consiste à faire réagir un 5-($g(a)-haloacétyl)-8-substitué oxy-( lH)-quinolin-2-one avec un agent réducteur en présence d'un agent chiral et d'une base afin de former un 8-(substitué oxy)-5-((R)-2-halo-l-hydroxy-éthyl)-( lH)-quinolin-2-one; lequel agent chiral étant représenté par la formule (I) ou par la formule (II), dans ces formules. M, L, X, R1, R2 et R3 sont tels que définis dans la description.
MA29571A 2004-06-22 2006-12-28 Composes organiques MA28687B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0413960.6A GB0413960D0 (en) 2004-06-22 2004-06-22 Organic compounds

Publications (1)

Publication Number Publication Date
MA28687B1 true MA28687B1 (fr) 2007-06-01

Family

ID=32799952

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29571A MA28687B1 (fr) 2004-06-22 2006-12-28 Composes organiques

Country Status (32)

Country Link
US (2) US20090054653A1 (fr)
EP (1) EP1791820B1 (fr)
JP (1) JP5064214B2 (fr)
KR (1) KR101179302B1 (fr)
CN (1) CN1968927B (fr)
AR (2) AR049553A1 (fr)
AT (1) ATE450512T1 (fr)
AU (1) AU2005254698B2 (fr)
BR (1) BRPI0512298A (fr)
CA (1) CA2566388C (fr)
CY (1) CY1109884T1 (fr)
DE (1) DE602005018076D1 (fr)
DK (1) DK1791820T3 (fr)
EC (1) ECSP067100A (fr)
ES (1) ES2337273T3 (fr)
GB (1) GB0413960D0 (fr)
HR (1) HRP20100087T1 (fr)
IL (1) IL179600A (fr)
MA (1) MA28687B1 (fr)
MX (1) MXPA06014695A (fr)
MY (1) MY142051A (fr)
NO (1) NO339079B1 (fr)
NZ (1) NZ551276A (fr)
PE (1) PE20060304A1 (fr)
PL (1) PL1791820T3 (fr)
PT (1) PT1791820E (fr)
RU (1) RU2383534C2 (fr)
SI (1) SI1791820T1 (fr)
TN (1) TNSN06408A1 (fr)
TW (1) TWI347317B (fr)
WO (1) WO2005123684A2 (fr)
ZA (1) ZA200609257B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198450B2 (en) 2006-06-30 2012-06-12 Novartis Ag Quinolinone derivatives and their pharmaceutical compositions
EP1914227A1 (fr) * 2006-08-31 2008-04-23 Novartis AG Forme crystalline polymorphe d'une dérivé de indan-2-ylamino-hydroxyethyl-quinolinone maleate comme agoniste de 2-adrénorécepteur beta
WO2011056929A1 (fr) 2009-11-04 2011-05-12 Massachusetts Institute Of Technology Synthèse en flux continu d'alcools aminés à l'aide de microréacteurs
US8680303B2 (en) 2010-03-01 2014-03-25 Massachusetts Institute Of Technology Epoxidation catalysts
MX2013000537A (es) 2010-07-14 2013-01-29 Novartis Ag Compuestos heterociclicos agonistas del receptor ip.
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
ES2565826T3 (es) 2012-01-13 2016-04-07 Novartis Ag Pirroles fusionados como agonistas del receptor IP para el tratamiento de hipertensión arterial pulmonar (PAH) y trastornos relacionados
EP2802585A1 (fr) 2012-01-13 2014-11-19 Novartis AG Pipéridines condensées utilisées comme agonistes du récepteur ip pour le traitement de l'htap et de troubles connexes
EP2802582A1 (fr) 2012-01-13 2014-11-19 Novartis AG Dihydropyrido [2,3-b]pyrazines fusionnées comme agonistes des récepteurs ip pour le traitement de l'hypertension artérielle pulmonaire (hap) et des troubles connexes
WO2013105063A1 (fr) 2012-01-13 2013-07-18 Novartis Ag Pipéridines condensées utilisées comme agonistes du récepteur ip pour le traitement de l'hypertension artérielle pulmonaire (htap) et de troubles associés
WO2013105066A1 (fr) 2012-01-13 2013-07-18 Novartis Ag Sels d'un agoniste du récepteur ip
EP2802581A1 (fr) 2012-01-13 2014-11-19 Novartis AG 7,8-dihydropyrido[3,4-b]pyrazines utilisées comme agonistes du récepteur ip pour le traitement de l'hypertension artérielle pulmonaire (htap) et des troubles associés
CN104379566B (zh) * 2012-07-11 2016-08-24 上海威智医药科技有限公司 茚达特罗中间体及茚达特罗的合成方法
WO2014044288A1 (fr) 2012-09-21 2014-03-27 Crystal Pharma Sa Procédés de préparation d'indacatérol et de ses sels pharmaceutiquement acceptables
EP3138837B1 (fr) 2012-09-21 2021-11-24 Crystal Pharma, S.A.U. Base libre d'indacatérol sous forme solide
JP6363616B2 (ja) 2012-12-19 2018-07-25 ノバルティス アーゲー オートタキシン阻害剤
JP2016507582A (ja) 2013-02-13 2016-03-10 ノバルティス アーゲー Ｉｐ受容体アゴニスト複素環式化合物
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
WO2014141069A1 (fr) 2013-03-14 2014-09-18 Novartis Ag Désamorphisation de formulations séchées par pulvérisation par l'intermédiaire d'un mélange par pulvérisation
CZ306252B6 (cs) 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
EP3205646A3 (fr) 2013-03-27 2017-10-04 Laboratorios Lesvi, S.L. Intermédiaires pour la fabrication de (r)-5-[2- (5,6-diéthylindan-2-ylamino)-1-hydroxyéthyl]-8-hydroxy-(1h)-quinolin-2-one (indacatérol)
SG11201600241RA (en) 2013-07-18 2016-02-26 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
WO2015008229A1 (fr) 2013-07-18 2015-01-22 Novartis Ag Inhibiteurs de l'autotaxine
WO2015104718A2 (fr) 2014-01-09 2015-07-16 Davuluri, Ramamohan Rao Nouveau procédé de préparation d'indacatérol ou de ses sels pharmaceutiquement acceptables
CN106102724A (zh) 2014-03-27 2016-11-09 诺华股份有限公司 用于吸入活性药物成分的经喷雾干燥的水包油包固体分散系
US20170037030A1 (en) 2014-04-24 2017-02-09 Novartis Ag Autotaxin inhibitors
CN105693603B (zh) * 2014-11-24 2019-11-29 上海医药工业研究院 改良的马来酸茚达特罗制备工艺
KR101769204B1 (ko) * 2015-08-04 2017-08-17 씨제이헬스케어 주식회사 크로마놀 유도체의 신규한 제조방법
ES2747905T3 (es) 2015-09-29 2020-03-12 Inke Sa Solvato mixto de L-tartrato de (R)-5-[2-(5,6-dietilindan-2-ilamino)-1-hidroxietil]-8-hidroxi-1H-quinolin-2-ona
CN107394260B (zh) * 2016-05-17 2020-06-09 财团法人工业技术研究院 金属离子电池
CN107868045A (zh) * 2016-09-28 2018-04-03 四川海思科制药有限公司 一种茚达特罗中间体的制备方法
CN114591236A (zh) * 2020-12-02 2022-06-07 四川海思科制药有限公司 一种茚达特罗的改进制备方法
CN113731406B (zh) * 2021-10-12 2023-07-28 南京工业大学 一种提高钯碳活性加氢脱除保护基的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
DE69738949D1 (de) * 1996-05-20 2008-10-09 Darwin Discovery Ltd Chinolincarboxamide als tnf-inhibitoren und als pde-iv inhibitoren
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
TWI324150B (en) * 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
PE20050211A1 (es) * 2003-04-02 2005-04-27 Novartis Ag Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas

Also Published As

Publication number Publication date
CA2566388C (fr) 2013-04-16
DE602005018076D1 (de) 2010-01-14
EP1791820A2 (fr) 2007-06-06
KR20070029752A (ko) 2007-03-14
BRPI0512298A (pt) 2008-03-25
CN1968927B (zh) 2010-07-21
CY1109884T1 (el) 2014-09-10
ECSP067100A (es) 2007-01-26
US20120220775A1 (en) 2012-08-30
DK1791820T3 (da) 2010-04-06
GB0413960D0 (en) 2004-07-28
US20090054653A1 (en) 2009-02-26
PE20060304A1 (es) 2006-05-19
KR101179302B1 (ko) 2012-09-03
RU2007102228A (ru) 2008-07-27
HK1105121A1 (en) 2008-02-01
ES2337273T3 (es) 2010-04-22
NO339079B1 (no) 2016-11-07
IL179600A (en) 2011-11-30
MY142051A (en) 2010-08-30
JP2008503526A (ja) 2008-02-07
HRP20100087T1 (hr) 2010-06-30
AR049553A1 (es) 2006-08-16
CA2566388A1 (fr) 2005-12-29
RU2383534C2 (ru) 2010-03-10
NZ551276A (en) 2010-06-25
IL179600A0 (en) 2007-05-15
TNSN06408A1 (en) 2008-02-22
MXPA06014695A (es) 2007-02-12
PT1791820E (pt) 2010-02-23
JP5064214B2 (ja) 2012-10-31
AR082981A2 (es) 2013-01-23
WO2005123684A2 (fr) 2005-12-29
CN1968927A (zh) 2007-05-23
TW200615265A (en) 2006-05-16
PL1791820T3 (pl) 2010-05-31
EP1791820B1 (fr) 2009-12-02
ZA200609257B (en) 2008-07-30
WO2005123684A3 (fr) 2006-06-01
SI1791820T1 (sl) 2010-04-30
TWI347317B (en) 2011-08-21
ATE450512T1 (de) 2009-12-15
NO20070400L (no) 2007-03-21
AU2005254698B2 (en) 2008-09-25
AU2005254698A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
MA28687B1 (fr) Composes organiques
UY28211A1 (es) Compuestos de hidroximetilo
NO20082719L (no) Aryl-isoksazol-4-yl-oksadiazolderivater
MA30991B1 (fr) Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4
WO2008114819A1 (fr) Nouveau composé d'adénine
MA31763B1 (fr) Inhibiteurs de kinase de type polo
MA30411B1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
WO2005092858A3 (fr) Composes alpha-aryle ou heteroaryle methyle beta piperidino propanamide en tant qu'antagoniste du recepteur orl1
DE60128343D1 (de) Pyrimidine verbindungen
TW200611907A (en) Fused heterocyclic compound
DE60236719D1 (de) Purinderivate als antagonisten an purinergen rezeptoren
AR060331A1 (es) Un proceso convergente para la sintesis de derivados de taxano
MA31832B1 (fr) Dérivés de quinazolinedione, leur préparation et leurs applications thérapeutiques
MA31170B1 (fr) Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer
MA29563B1 (fr) Composes organiques
PE20061067A1 (es) Derivados de pirimidina
EP2036905A4 (fr) Dérivé de pyridylisoxazole
TNSN07400A1 (fr) Derives d'aminoacides
MA27930A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4
MA31015B1 (fr) Procede de fabrication de 4.4'- (1-methyl-1,2-ethandiyl)-bis -(2,6-piperazindione)
KR880013920A (ko) 디하이드로피리딘 화합물 및 이의 제조방법
GB0412314D0 (en) Compounds
EP1757610A4 (fr) Derivé de pyrimidine condensé et inhibiteur de la xanthine oxydase
EP1238977A4 (fr) Procede de preparation d'un compose pyridinemethanol
PE20061078A1 (es) Derivados de piridotienopirimidina como inhibidores de la fosfodiesterasa 4 (pde4)